OSLO /LONDON ,JANUARY 26th 2021 :EXACT THERAPEUTICS AS ("EXACT-Tx" or the "Company"), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announced the appointment of DrHilary McElwaine-Johnn as Chief Medical Officer.Dr McElwaine-Johnn will be based at the newly openedLondon office of EXACT-Tx at the Translation & Innovation Hub (i-Hub) at White City. "We are delighted to welcome Hilary toEXACT Therapeutics AS where her unique experience in both therapeutics and drug delivery complemented by deep medical expertise will be pivotal in driving forward the development of ACT®, both in the ongoing Phase I ACTIVATE study and beyond", said DrRafiq Hasan , CEO ofEXACT Therapeutics AS . "Hilary joins EXACT-Tx at an exciting time as we expand our presence in theUK with the opening of ourLondon office at the White City i-Hub in close proximity to the growingImperial College campus".Dr McElwaine-Johnn gained her medical degree fromImperial College, London and is a Member of theRoyal College of Physicians and Faculty of Pharmaceutical Medicine . Following clinical roles in general internal medicine and oncology, she has pursued a highly successful career in the pharmaceutical industry. She has held a variety of senior medical positions including Vice President, Clinical,PowderMed Ltd (which was subsequently acquired byPfizer ), Chief Medical Officer ofVantia Ltd ,PsiOxus Therapeutics Ltd and most recentlyKarus Therapeutics . During this time Hilary has gained extensive experience in drug development in both oncology and other therapeutic indications as well as delivery technologies complemented by a range of successful interactions with Regulatory Authorities, partner companies and fundraising activities.Dr McElwaine-Johnn commented: "I am excited to be joining EXACT Therapeutics inLondon to be part of a dynamic and innovative organization exploring the potential of the ACT® platform to transform clinical practice across indications, particularly in the management of patients with cancer. With a strong preclinical evidence base and clinical development of ACT® already underway, I am looking forward to working with the clinical community in further investigating this exciting approach to ultrasound mediated therapeutic targeting." About ACT® o ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration. o Initial focus of the company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes. About EXACT EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com For more information contact: DrRafiq Hasan , CEO EXACT Therapeutics Rafiq@exact-tx.comRichard Hayhurst /Janet Joy Tel +44 7711 821527 richard@rhapr.eu
Click here for more information
© Oslo Bors ASA, source